Compare SF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SF | PCVX |
|---|---|---|
| Founded | 1890 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 7.0B |
| IPO Year | 1994 | 2020 |
| Metric | SF | PCVX |
|---|---|---|
| Price | $70.99 | $59.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $80.88 | ★ $116.40 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.23 | N/A |
| Revenue | ★ $6,347,533,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $7.90 | N/A |
| P/E Ratio | $17.17 | ★ N/A |
| Revenue Growth | ★ 6.65 | N/A |
| 52 Week Low | $65.40 | $42.40 |
| 52 Week High | $134.74 | $90.75 |
| Indicator | SF | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 42.72 |
| Support Level | $68.47 | $58.85 |
| Resistance Level | $71.29 | $62.44 |
| Average True Range (ATR) | 1.84 | 2.93 |
| MACD | 0.41 | -0.39 |
| Stochastic Oscillator | 56.13 | 1.68 |
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a Saint Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.